ClinicalTrials.gg
Active, not recruitingNCT06474416Updated May 18, 2025

A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis

A Phase 1 interventional study of BD111 Injection (Investigative New Drug) and Triple-drugs therapy of HSV-1 stromal keratitis in Herpes Simplex Virus Type I Stromal Keratitis, sponsored by Shanghai BDgene Co., Ltd.. Active, not recruiting at 3 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Shanghai BDgene Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as active, not recruiting.
  • Registered 9 months after the study started (first participant enrolled Sep 2023, registered Jun 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This Phase I study is intended to evaluate the safety, tolerability, PK/PD profiles and preliminary efficacy via corneal intrastromal administration in patients with herpes simplex virus-1 stromal keratitis (HSK), with a dose exploration of four ascending doses of BD111 (investigative drug product).

Read the detailed description

Herpes simplex keratitis is an infectious diseases of the cornea that is primarily caused by Herpes Simplex Virus 1 (HSV-1). The stromal type, also known as HSV-1 stromal keratitis (HSK), is characterized by recurrent or chronic inflammation attributed to residual virus-triggered antigen-antibody-complement cascade reactions. BD111 is a lentivirus-like particle that is an active drug substance delivering gRNA-expressing cassettes and SpCas9 mRNA.The mechanism of action (MOA) is based on CRISPR/Cas9 gene editing technology.

This is a multicenter, open-label, dose-escalation, Phase I trial to evaluate the safety, tolerability, PK/PD profiles and preliminary efficacy of BD111 in patients with herpes simplex virus-1 stromal keratitis (HSK) in China. About 16 patients will be enrolled, dividing into open-label, four dose groups and one positive control (triple-drugs therapy) group. A rapid titration dose group combined with "3+3" dose escalation is designed for dose exploration.

02

Conditions studied

  • Herpes Simplex Virus Type I Stromal Keratitis

Keywords

  • Herpes simplex keratitis
  • Herpes Simplex Virus Type I
  • Stromal Keratitis
03

In context

Lead sponsor

Shanghai BDgene Co., Ltd. is the lead sponsor of 10 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Participants must meet all of the following inclusion criteria to be enrolled in this study

  1. Aged 18 to 70 years old;
  2. Clinically diagnosed patients with recurrent herpes simplex virus type I stromal keratitis (HSK). Definition of recurrence: the patient had been diagnosed with HSK and received "local antiviral eye drugs and oral antiviral drugs + local eye drops" for 3 weeks with successful clinical efficacy. Before enrollment, the clinical recurrence of HSK occurred again with symptoms including tearing, photophobia, pain, blurred vision and foreign body sensation, and signs as recurrence of active inflammatory lesions examined by slit lamp;
  3. HSV-1 nucleic acid test (qPCR method) positive;
  4. No use of other systemic antiviral drugs or corticosteroids within 48 hours before enrollment;
  5. No systemic immune diseases;
  6. Good eyelid structure and blinking function;
  7. Eye structure and function assessment showing potential for visual recovery;
  8. No retinal detachment;
  9. No history of corneal trauma;
  10. The best visual acuity in the fellow eye (BCVA) ≥ 38 (ETDRS);
  11. Fertile males or females must use highly effective methods, such as, oral contraceptives, intrauterine devices, abstinence, or barrier contraception combined with spermicides, during the trial and continue contraception for 12 months after administration;
  12. Participants voluntarily join the study, sign an form, have good compliance, and cooperate with follow-up visits.

Exclusion Criteria: Patients with any of the following conditions cannot be enrolled in this study

  1. Active ocular infection caused by other pathogens in the target eye or the fellow eye within 30 days before enrollment, including but not limited to infectious conjunctivitis, keratitis, scleritis, and endophthalmitis;
  2. Patients with bilateral viral keratitis
  3. Previous corneal transplant surgery in the study eye;
  4. Any medicine or food allergic history;
  5. Absence of tear film and blinking function;
  6. Severe dry eye disease;
  7. Ocular surface tumor;
  8. Glaucoma;
  9. Patients with systemic diseases;
  10. Signs of systemic infection before enrollment, including fever and receiving antibiotic treatment (systemic infection in this trial is defined as abnormal values in white blood cells, lymphocytes, and neutrophils in routine blood tests);
  11. Severe diseases in the major organs including but not limited to cardiovascular, lung, liver, kidney, or other uncontrolled diseases;
  12. infection;
  13. Pregnant and lactating women (pregnancy in this trial is defined as a positive urine or blood pregnancy test);
  14. Participation in other drug or medical device clinical trials at present;
  15. Alcohol or drug abuse;
  16. Lack of compliance with the trial or the ability to sign an informed consent form;
  17. Other situations deemed unsuitable for participation in the trial by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    BD111 dose 1 group

    1.25E+06 TU/eye

    Genetic: BD111 Injection (Investigative New Drug)

  • Experimental
    BD111 dose 2 group

    2.5E+06 TU/eye

    Genetic: BD111 Injection (Investigative New Drug)

  • Experimental
    BD111 dose 3 group

    5.0E+06TU/eye

    Genetic: BD111 Injection (Investigative New Drug)

  • Experimental
    BD111 dose 4 group

    10E+06 TU/eye

    Genetic: BD111 Injection (Investigative New Drug)

  • Active comparator
    Positive control group

    Triple-drugs therapy group: "Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops" for 3 weeks.

    Combination Product: Triple-drugs therapy of HSV-1 stromal keratitis

Interventions

  • GeneticBD111 Injection (Investigative New Drug)

    BD111 Injection (Investigative New Drug) is a type of lentiviral-like particle, which can simultaneously deliver SpCas9 and gRNA targeting the HSV-1 virus gene, also known as HSV-1-erasing lentiviral particles (HELP).

    Also known as: BD111 Lentivirus-like particles, HSV-1-erasing lentiviral particles, HELP

  • Combination productPrednisolone acetateStudies of Prednisolone acetatePrednisolone acetate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Triple-drugs therapy: "Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops" for 3 weeks.

    Also known as: Ganciclovir Ophthalmic Gel, Valacyclovir Hydrochloride Tablets, Prednisolone Acetate Ophthalmic Suspension

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    DLT is defined as toxicity related to BD111 observed by the investigator and sponsor during the treatment period, specifically: a) Endophthalmitis; b) Corneal perforation; c) Hypopyon; d) Other toxicities that are significantly worse than baseline or defined as ≥ Grade 4 ocular toxicity and persist for 14 days or longer, which require trial termination after discussion with the investigator and sponsor; e) Any non-ocular Grade ≥ 3 abnormality that persists for more than 1 week or requires hospitalization for medical intervention; f) death.

    Time frame: 12 months

  2. Maximum tolerated dose (MTD)

    The highest dose at which ≤1/3 of the subjects experience DLT during the DLT observation period. The MTD dose must be confirmed in at least 6 subjects.

    Time frame: 12 months

  3. Recommended Phase 2 dose (RP2D)

    The RP2D is determined by integrating safety, pharmacokinetic, and efficacy data from the comprehensive dose escalation. Typically, the MTD (DLT incidence ≤ 1/3) is used as the RP2D when it is confirmed, or a dose lower than the MTD is selected as the RP2D based on comprehensive data.

    Time frame: 12 months

  4. Incidence and characteristics of adverse events (AE) and serious adverse events (SAE) during the study

    AE and SAE are recorded and evaluated, including eye-related AEs after treatment, such as AE at the corneal injection site.

    Time frame: 12 months

Secondary outcomes

  1. Tear fluid vector RNA

    Tear fluid vector RNA copy numbers detected by real-time qPCR test, is one of Pharmacokinetics indicators of main components of BD111, and analysizing results will be used to evaluated the PK profile of tear fluid vector RNA and dose-response relationship of BD111.

    Time frame: 12 months

  2. Tear fluid vector circular DNA

    Tear fluid vector circular DNA copy numbers detected by real-time qPCR test, is another Pharmacokinetics indicator of main components of BD111, and analysizing results will be used to evaluated the PK profile of tear fluid vector RNA and dose-response relationship of BD111.

    Time frame: 12 months

  3. Blood vector circular DNA

    Real-time qPCR test will be used to detect copy number of vector circular DNA in blood, analysizing the PK profile of blood vector circular DNA and dose-response relationship of BD111.

    Time frame: 12 months

  4. Blood p24 protein

    P24 protein concentration in blood will be assayed using ELISA p24 kit at preseted timepoints, analysizing the PK profile of Blood p24 protein.

    Time frame: 12 months

  5. Blood Cas9 protein

    Cas9 protein concentration in blood will be assayed using ELISA p24 kit at preseted timepoints, analysizing the PK profile of Blood p24 protein.

    Time frame: 12 months

  6. Off-target Detection (Not applicable to comparison group)

    BD111 off-target test of eye swabs samples will be conducted by DNA deep sequencing at Day 0, Day6 and Day 180 post-administration.

    Time frame: 12 months

  7. Antibodies to BD111-related ingredients (anti-drug antibodies, no applicable to comparison group)

    Including: a) Anti-p24 antibody in the participants' blood samples at Day 0, Day 14, Day 28, Day 180 and Day 365; b) Anti-Cas9 antibody in the participants' blood samples at Day 0, Day 14, Day 28, Day 180 and Day 365; c) Anti-BD111 antibody in the participants' blood samples at Day 0, Day 14, Day 28, Day 180 and Day 365.

    Time frame: 12 months

  8. The percentage of participants with successful clearance of HSV-1 viral genome in tear at Day 14, Day 28, Day 70, Day 112, Day 180, and Day 365 post-administration

    The definition of successful HSV-1 clearance: negative results in tear swab HSV-1 nucleic acid tests on two consecutive samplings (interval ≥14 days). The definition of a negative result in tear swab HSV-1 nucleic acid test: single qPCR Ct value = 40 or "undetected", or Ct value of the first qPCR test "36 \< Ct value \< 40", and the Ct value of repetitive qPCR test is 40 or "undetected".

    Time frame: 12 months

  9. The percentage of participants with failed clearance of HSV-1 viral genome in tears at Day 14, Day 28, Day 70, Day 112, Day 180, and Day 365 post-administration

    The failure of HSV-1 viral genome clearance is determinated by HSV-1 positive results of qPCR test. HSV-1 positive definition of qPCR test: qPCR Ct value ≤ 36, or qPCR Ct value is "36 \< Ct value \< 40" and the Ct value of repetitive qPCR test is ≤ 36, or results of both qPCR tests are "36 \< Ct value \< 40".

    Time frame: 12 months

  10. Clinical cure rate of HSK at Day 70 and Day112 post-administration

    Definition of HSK clinical cure: disappearance of the subject's clinical symptoms, disappearance of active inflammatory lesions on ophthalmologic examinations, and successful clearance of the HSV-1 viral genome.

    Time frame: 12 months

  11. The percentage of participants with HSK recurrence at Day 180, and Day 365 post-administration

    Definition of HSK recurrence: HSV-1 nucleic acid qPCR test is positive, and clinical symptoms presents again, and ophthalmic examinations find active inflammatory lesions on interventional eye.

    Time frame: 12 months

  12. The score change of corneal inflammation scale post-administration

    The score changes of corneal inflammation scale will be essessed at Day 70, Day 112, Day 180, and Day 365 post-administration.

    Time frame: 12 months

  13. The improvement in best corrected visual acuity (BCVA)

    From baseline to Day 70, Day 112, Day 180, and Day 365 post-administration.

    Time frame: 12 months

  14. The improvement in corrected distance visual acuity (CDVA) post-administration

    From baseline to Day 70, D11ay 2, Day 180, and Day 365 post-administration.

    Time frame: 12 months

Other outcomes

  1. Anti-p24 antibody in blood

    At Day 14, Day 28, Day 180, and Day 365 post-administration.

    Time frame: 12 months

  2. Anti-Cas9 antibody in blood

    At Day 14, Day 28, Day 180, and Day 365 post-administration.

    Time frame: 12 months

  3. Anti-BD111 antibody in blood

    At Day 14, Day 28, Day 180, and Day 365 post-administration.

    Time frame: 12 months

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Oct 2025, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 25, 2024
StartActual
Sep 4, 2023
Primary completionEst.
Oct 2025
CompletionEst.
Mar 13, 2026
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06474416
Lead sponsor
Shanghai BDgene Co., Ltd.
Responsible party
Sponsor
First posted
Jun 25, 2024
Start date
Sep 4, 2023
Primary completion
Oct 2025 (estimated)
Completion
Mar 13, 2026 (estimated)
Last update
May 18, 2025

Study contacts

Wei Chen, M.D.
principal investigator · No. 270, West Academy Road, Wenzhou, Zhejiang, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion